351 related articles for article (PubMed ID: 32056030)
1. The Complex Interplay Between Inflammatory Bowel Disease and Malignancy.
Kimmel J; Axelrad J
Curr Gastroenterol Rep; 2020 Feb; 22(3):13. PubMed ID: 32056030
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy.
Hasan B; Tandon KS; Miret R; Khan S; Riaz A; Gonzalez A; Rahman AU; Charles R; Narula N; Castro FJ
J Gastroenterol Hepatol; 2022 Jun; 37(6):1016-1021. PubMed ID: 35191100
[TBL] [Abstract][Full Text] [Related]
3. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports.
Momen Majumder MS; Haq SA; Rasker JJ
J Med Case Rep; 2023 Mar; 17(1):71. PubMed ID: 36855206
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
6. Pancreatitis in inflammatory bowel diseases.
Pitchumoni CS; Rubin A; Das K
J Clin Gastroenterol; 2010 Apr; 44(4):246-53. PubMed ID: 20087199
[TBL] [Abstract][Full Text] [Related]
7. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
[TBL] [Abstract][Full Text] [Related]
8. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease.
Rajca S; Seksik P; Bourrier A; Sokol H; Nion-Larmurier I; Beaugerie L; Cosnes J
J Crohns Colitis; 2014 Aug; 8(8):819-24. PubMed ID: 24439392
[TBL] [Abstract][Full Text] [Related]
9. Obesity and novel management of inflammatory bowel disease.
Kim JH; Oh CM; Yoo JH
World J Gastroenterol; 2023 Mar; 29(12):1779-1794. PubMed ID: 37032724
[TBL] [Abstract][Full Text] [Related]
10. Bone density improves with disease remission in patients with inflammatory bowel disease.
Reffitt DM; Meenan J; Sanderson JD; Jugdaohsingh R; Powell JJ; Thompson RP
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1267-73. PubMed ID: 14624148
[TBL] [Abstract][Full Text] [Related]
11. [Cancer Surveillance in Inflammatory Bowel Diseases].
Lissner D; Siegmund B
Dtsch Med Wochenschr; 2019 Jun; 144(11):753-756. PubMed ID: 31163475
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ustekinumab in the Inflammatory Bowel Disease of Chronic Granulomatous Disease.
Bhattacharya S; Marciano BE; Malech HL; Quezado M; Holland SM; De Ravin SS; Zerbe CS; Heller T
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):461-464.e2. PubMed ID: 33813069
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Disorders in Patients with Inflammatory Bowel Disease.
Montenegro ML; Corral JE; Lukens FJ; Ji B; Kröner PT; Farraye FA; Bi Y
Dig Dis Sci; 2022 Feb; 67(2):423-436. PubMed ID: 33625614
[TBL] [Abstract][Full Text] [Related]
14. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.
Masunaga Y; Ohno K; Ogawa R; Hashiguchi M; Echizen H; Ogata H
Ann Pharmacother; 2007 Jan; 41(1):21-8. PubMed ID: 17200426
[TBL] [Abstract][Full Text] [Related]
17. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
18. The use of medications for inflammatory bowel disease during pregnancy and nursing.
Sauk J; Kane S
Expert Opin Pharmacother; 2005 Sep; 6(11):1833-9. PubMed ID: 16144504
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
Vedamurthy A; Gangasani N; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312
[TBL] [Abstract][Full Text] [Related]
20. Treatment of inflammatory bowel disease (IBD).
Pithadia AB; Jain S
Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
